Battelle believes its electrohydrodynamic (EHD) technology can deliver drugs to the lung to treat asthma, emphysema, cancers of the lung, and other conditions more effectively than existing commercial inhalation systems. Drug companies are interested, as evidenced by the company's deals with Pfizer, the Ross Products division of Abbott, and others. Battelle is partnering EHD and also developing an internally developed inhaled chemotherapy system on its own.

Electrosols Ltd. has drug delivery technology suitable for pulmonary delivery, based on tiny, uniform sized particles that can be manipulated with electrical fields.